[go: up one dir, main page]

AR119047A1 - Esteroides neuroactivos como moduladores de gabaa y su uso en el tratamiento de trastornos del snc - Google Patents

Esteroides neuroactivos como moduladores de gabaa y su uso en el tratamiento de trastornos del snc

Info

Publication number
AR119047A1
AR119047A1 ARP200101529A ARP200101529A AR119047A1 AR 119047 A1 AR119047 A1 AR 119047A1 AR P200101529 A ARP200101529 A AR P200101529A AR P200101529 A ARP200101529 A AR P200101529A AR 119047 A1 AR119047 A1 AR 119047A1
Authority
AR
Argentina
Prior art keywords
substituted
unsubstituted
rga
group
alkyl
Prior art date
Application number
ARP200101529A
Other languages
English (en)
Inventor
Francesco G Salituro
Maria Jesus Blanco-Pillado
Marshall Lee Morningstar
Original Assignee
Sage Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sage Therapeutics Inc filed Critical Sage Therapeutics Inc
Publication of AR119047A1 publication Critical patent/AR119047A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0011—Androstane derivatives substituted in position 17 by a keto group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0018—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa
    • C07J1/0022—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J11/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
    • C07J13/007—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 17 (20)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J21/005—Ketals
    • C07J21/008—Ketals at position 17
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/003—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring the S atom directly linked to a ring carbon atom of the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0088—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing unsubstituted amino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0094—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0007—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond not substituted in position 17 alfa
    • C07J5/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond not substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
    • C07J7/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
    • C07J7/002—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/0065—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by an OH group free esterified or etherified
    • C07J7/007—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by an OH group free esterified or etherified not substituted in position 17 alfa
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
    • C07J7/0085—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21 by an halogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
    • C07J7/0095—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21 carbon in position 21 is part of carboxylic group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/001—Oxiranes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Compuestos esteroides con actividad moduladora de GABAA, composiciones farmacéuticas que los comprenden y su uso para el tratamiento de trastornos del SNC, en particular un trastorno de humor tal como depresión y específicamente un trastorno de depresión severo y depresión posparto. Reivindicación 1: Un compuesto de la fórmula (1) o una sal farmacéuticamente aceptable de este; caracterizado porque: ⁻ ⁻ ⁻ ⁻ ⁻ ⁻ representa un enlace simple o doble, siempre que haya un enlace doble presente, entonces uno de R⁶ᵃ o R⁶ᵇ está ausente y R⁵ está ausente; RX se selecciona del grupo que consiste en halo, -CN, -OH, -ORQ¹ y alquilo sustituido o no sustituido, donde RQ¹ es alquilo sustituido o no sustituido; RY es halo o alquilo sustituido o no sustituido o RY y RX pueden unirse con los átomos que intervienen para formar un carbociclilo sustituido o no sustituido o un heterociclilo sustituido o no sustituido; R³ se selecciona del grupo que consiste en alquilo sustituido o no sustituido, alquenilo sustituido o no sustituido, alquinilo sustituido o no sustituido, carbociclilo sustituido o no sustituido, heterociclilo sustituido o no sustituido, arilo sustituido o no sustituido y heteroarilo sustituido o no sustituido; R⁵ es hidrógeno o metilo; cada instancia de R²² se selecciona de forma independiente del grupo que consiste en halógeno, -NO₂, -CN, -ORGA, -N(RGA)₂, -C(=O)RGA, -C(=O)ORGA, -OC(=O)RGA, -OC(=O)ORGA, -C(=O)N(RGA)₂, -N(RGA)C(=O)RGA, -OC(=O)N(RGA)₂, -N(RGA)C(=O)ORGA, -N(RGA)C(=O)N(RGA)₂, -SRGA, -S(=O)RGA, -S(=O)₂RGA, -S(=O)₂ORGA, -OS(=O)₂RGA, -S(=O)₂N(RGA)₂, -N(RGA)S(=O)₂RGA, alquilo sustituido o no sustituido, alquenilo sustituido o no sustituido, alquinilo sustituido o no sustituido, carbociclilo sustituido o no sustituido, heterociclilo sustituido o no sustituido, arilo sustituido o no sustituido y heteroarilo sustituido o no sustituido, donde cada instancia de RGA se selecciona de forma independiente del grupo que consiste en hidrógeno, alquilo C₁₋₆ sustituido o no sustituido, alquenilo C₂₋₆ sustituido o no sustituido, alquinilo C₂₋₆ sustituido o no sustituido, carbociclilo C₃₋₆ sustituido o no sustituido, heterociclilo de 3 a 6 miembros sustituido o no sustituido, arilo sustituido o no sustituido, heteroarilo sustituido o no sustituido, un grupo protector de oxígeno cuando se une a oxígeno y un grupo protector de nitrógeno cuando se une a nitrógeno, o se toman dos grupos RGA con los átomos que intervienen para formar un anillo heterocíclico o heteroarilo sustituido o no sustituido; R¹ᵃ, R¹ᵇ, R²ᵃ, R²ᵇ, R⁴ᵃ, R⁴ᵇ, R⁷ᵃ, R⁷ᵇ, R¹¹ᵃ, R¹¹ᵇ, R¹²ᵃ y R¹²ᵇ se seleccionan cada uno de forma independiente del grupo que consiste en hidrógeno, halógeno, ciano, -NO₂, alquilo sustituido o no sustituido, alquenilo sustituido o no sustituido, alquinilo sustituido o no sustituido, carbociclilo sustituido o no sustituido, heterociclilo sustituido o no sustituido, arilo sustituido o no sustituido, heteroarilo sustituido o no sustituido, -ORA¹, -N(RA¹)₂, -SRA¹, -C(=O)RA¹, -C(=O)ORA¹, -C(=O)SRA¹, -C(=O)N(RA¹)₂, -OC(=O)RA¹, -OC(=O)ORA¹, -OC(=O)N(RA¹)₂, -OC(=O)SRA¹, -OS(=O)₂RA¹, -OS(=O)₂ORA¹, -OS(=O)₂N(RA¹)₂, -N(RA¹)C(=O)RA¹, -N(RA¹)C(=NRA¹)RA¹, -N(RA¹)C(=O)ORA¹, -N(RA¹)C(=O)N(RA¹)₂, -N(RA¹)C(=NRA¹) N(RA¹)₂, -N(RA¹)S(=O)₂RA¹, -N(RA¹)S(=O)₂ORA¹, -N(RA¹)S(=O)₂N(RA¹)₂, -SC(=O)RA¹, -SC(=O)ORA¹, -SC(=O)SRA¹, -SC(=O)N(RA¹)₂, -S(=O)₂RA¹, -S(=O)₂ORA¹ o -S(=O)₂N(RA¹)₂, donde cada instancia de RA¹ se selecciona de forma independiente del grupo que consiste en hidrógeno, alquilo C₁₋₆ sustituido o no sustituido, alquenilo C₂₋₆ sustituido o no sustituido, alquinilo C₂₋₆sustituido o no sustituido, carbociclilo C₃₋₆ sustituido o no sustituido, o heterociclilo de 3 a 6 miembros sustituido o no sustituido, arilo sustituido o no sustituido, heteroarilo sustituido o no sustituido, un grupo protector de oxígeno cuando se une a oxígeno, un grupo protector de nitrógeno cuando se une a nitrógeno y un grupo protector de azufre cuando se une a azufre, o se toman dos grupos RA¹ con los átomos que intervienen para formar un anillo heterocíclico sustituido o no sustituido; R⁶ᵃ y R⁶ᵇ se seleccionan cada uno de forma independiente del grupo que consiste en hidrógeno, halógeno, ciano, -NO₂, -OH, alquilo sustituido o no sustituido, alquenilo sustituido o no sustituido y alquinilo sustituido o no sustituido; o R⁶ᵃ y R⁶ᵇ se unen para formar un grupo oxo (=O); R¹⁵ᵃ, R¹⁵ᵇ, R¹⁶ᵃ y R¹⁶ᵇ se seleccionan cada uno de forma independiente del grupo que consiste en hidrógeno, halógeno, -CN, -NO₂, alquilo sustituido o no sustituido, alquenilo sustituido o no sustituido, alquinilo sustituido o no sustituido, carbociclilo sustituido o no sustituido, heterociclilo sustituido o no sustituido, arilo sustituido o no sustituido, heteroarilo sustituido o no sustituido, -ORC³, -N(RC³)₂, -SRC³, -C(=O)RC³, -C(=O)ORC³, -C(=O)SRC³, -C(=O)N(RC³)₂, -OC(=O)RC³, -OC(=O)ORC³, -OC(=O)N(RC³)₂, -OC(=O)SRC³, -OS(=O)₂RC³, -OS(=O)₂ORC³, -OS(=O)₂N(RC³)₂, -N(RC³)C(=O)RC³, -N(RC³)C(=NRC³)RC³, -N(RC³)C(=O)ORC³, -N(RC³)C(=O)N(RC³)₂, -N(RC³)C(=NRC³)N(RC³)₂, -N(RC³)S(=O)₂RC³, -N(RC³)S(=O)₂ORC³, -N(RC³)S(=O)₂N(RC³)₂, -SC(=O)RC³, -SC(=O)ORC³, -SC(=O)SRC³, -SC(=O)N(RC³)₂, -S(=O)₂RC³, -S(=O)₂ORC³ o -S(=O)₂N(RC³)₂, donde cada instancia de RC³ se selecciona de forma independiente del grupo que consiste en hidrógeno, alquilo C₁₋₆ sustituido o no sustituido, alquenilo C₂₋₆ sustituido o no sustituido, alquinilo C₂₋₆ sustituido o no sustituido, arilo sustituido o no sustituido, heteroarilo sustituido o no sustituido, carbociclilo sustituido o no sustituido o heterociclilo sustituido o no sustituido, un grupo protector de oxígeno cuando se une a oxígeno, un grupo protector de nitrógeno cuando se une a nitrógeno y un grupo protector de azufre cuando se une a azufre, o se toman dos grupos RC³ con los átomos que intervienen para formar un anillo heterocíclico sustituido o no sustituido; R¹⁹ es hidrógeno o alquilo sustituido o no sustituido y n se selecciona del grupo que consiste en 0, 1, 2 y 3.
ARP200101529A 2019-05-31 2020-05-29 Esteroides neuroactivos como moduladores de gabaa y su uso en el tratamiento de trastornos del snc AR119047A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962855435P 2019-05-31 2019-05-31

Publications (1)

Publication Number Publication Date
AR119047A1 true AR119047A1 (es) 2021-11-17

Family

ID=71787077

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP200101529A AR119047A1 (es) 2019-05-31 2020-05-29 Esteroides neuroactivos como moduladores de gabaa y su uso en el tratamiento de trastornos del snc

Country Status (24)

Country Link
US (5) US11643434B2 (es)
EP (1) EP3976628A1 (es)
JP (2) JP7670626B2 (es)
KR (1) KR20220016098A (es)
CN (1) CN114206900A (es)
AR (1) AR119047A1 (es)
AU (2) AU2020284110A1 (es)
BR (1) BR112021024033A2 (es)
CA (1) CA3139554A1 (es)
CL (1) CL2021003166A1 (es)
CO (1) CO2021015890A2 (es)
CR (2) CR20210629A (es)
DO (2) DOP2021000237A (es)
EC (1) ECSP21091076A (es)
IL (1) IL288410B1 (es)
JO (1) JOP20210293A1 (es)
MA (1) MA56046A (es)
MX (3) MX2021014515A (es)
PE (1) PE20230244A1 (es)
PH (1) PH12021553005A1 (es)
SA (1) SA521430928B1 (es)
SG (1) SG11202112391UA (es)
TW (2) TWI864010B (es)
WO (1) WO2020243488A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2681835C2 (ru) 2012-01-23 2019-03-13 Сейдж Терапьютикс, Инк. Лекарственные формы нейроактивных стероидов и способы лечения нарушений цнс
IL294306B2 (en) 2012-08-21 2024-01-01 Sage Therapeutics Inc Methods of treating epilepsy or status epilepticus
BR112015026380A8 (pt) 2013-04-17 2019-12-31 Sage Therapeutics Inc esteróides de c21-n-pirazolil 19-nor c3,3-dissubstituídos e métodos de uso destes
US10246482B2 (en) 2014-06-18 2019-04-02 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
EP3719029A1 (en) 2014-11-27 2020-10-07 Sage Therapeutics, Inc. Compositions for inducing sedation
AR109393A1 (es) 2016-08-23 2018-11-28 Sage Therapeutics Inc Un esteroide 19-nor-c21-pirazolilo c3,3-disustituido cristalino
JP2021505608A (ja) 2017-12-08 2021-02-18 セージ セラピューティクス， インコーポレイテッド ＣＮＳ障害を処置するためのジュウテリウム化された２１−［４−シアノ−ピラゾール−１−イル］−１９−ノル−プレガン−３．α−オール−２０−オン誘導体
EP3902818A1 (en) 2018-12-05 2021-11-03 Sage Therapeutics, Inc. Neuroactive steroids and their methods of use
AU2020275291A1 (en) 2019-05-10 2021-11-25 Brii Biosciences, Inc. Pharmaceutical composition containing brexanolone, ganaxolone, or zuranolone, and use thereof
HUE068694T2 (hu) 2019-05-31 2025-01-28 Janssen Pharmaceutica Nv NF-KB indukáló kináz kismolekulás inhibitorai
WO2020264509A1 (en) * 2019-06-27 2020-12-30 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
US20230118577A1 (en) * 2020-01-12 2023-04-20 Brii Biosciences, Inc. Neuroactive steroids and pharmaceutical composition containing the same
EP4110345A4 (en) * 2020-02-27 2024-05-15 Brii Biosciences, Inc. NEUROACTIVE STEROID PRODRUGS
IL296371A (en) * 2020-03-18 2022-11-01 Sage Therapeutics Inc Neuroactive steroids and methods of using them

Family Cites Families (129)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2856415A (en) 1957-11-13 1958-10-14 Searle & Co 3,19-dihydroxy-5-androstene derivatives
FR1380417A (fr) 1962-05-15 1964-12-04 Roussel Uclaf Nouveaux androstanyl-pyrazoles et procédé de préparation
US3206459A (en) 1962-10-19 1965-09-14 Syntex Corp 10alpha-pregnan-19-ol derivatives
US3169134A (en) 1963-03-21 1965-02-09 Searle & Co 2, 3-oxygenated-17alpha-methyl-5alpha-androstan-17beta-ols
FR2969M (fr) 1963-05-22 1964-11-30 Roussel Uclaf Nouveau médicament notamment pour le traitement des spasmes d'origine coronarienne on viscérale.
BE754111A (fr) 1969-07-29 1971-01-29 Upjohn Co Nouveaux 7alpha- et 7beta-methyl-3alpha,5alpha- cycloandrostanes et composes analogues 19-nor et leur procede de preparation
GB1434919A (en) 1972-06-15 1976-05-12 Glaxo Lab Ltd 3alpha-hydroxy androstanes
GB1380246A (en) 1970-12-17 1975-01-08 Glaxo Lab Ltd 3alpha-hydroxy-androstanes and esters thereof
US3943124A (en) 1970-12-17 1976-03-09 Gordon Hanley Phillipps Chemical compounds
GB1430942A (en) 1972-05-05 1976-04-07 Glaxo Lab Ltd 21-substituted 3alpha-hydroxy pregnanes
US3983111A (en) 1972-05-05 1976-09-28 Glaxo Laboratories Limited Steroidal anaesthetics of the pregnane and 19-norpregnane series
GB1436324A (en) 1972-05-12 1976-05-19 Glaxo Lab Ltd Anaesthetic 3alpha-hydroxy pregnanes
ES432106A1 (es) 1973-11-30 1976-11-01 Schering Ag Procedimiento para la preparacion de d-homo-20-cetopregna- nos.
US4071625A (en) 1974-05-13 1978-01-31 Richardson-Merrell Inc. 19-Oxygenated-5α-androstanes for the enhancement of libido
DE2438020A1 (de) 1974-08-05 1976-02-26 Schering Ag 18-methyl-19-nor-20-keto-pregnane und verfahren zu ihrer herstellung
IL48628A0 (en) 1974-12-23 1976-02-29 Schering Ag D-homo-20-keto-pregnanes and process for their manufactur
DE2526373C2 (de) 1975-06-11 1983-11-10 Schering AG, 1000 Berlin und 4709 Bergkamen Verfahren zur Herstellung von Δ↑9↑↑(↑↑1↑↑1↑↑)↑-5α-20-Ketosteroiden
US4192871A (en) 1976-01-06 1980-03-11 Glaxo Laboratories Limited Chemical compounds
GB1570394A (en) 1976-01-06 1980-07-02 Glaxo Lab Ltd 11-acyloxy-3-hydroxy steroids
GB1581234A (en) 1976-04-05 1980-12-10 Glaxo Operations Ltd 11a - amino - 3a - hydroxysteroids
DE2632677A1 (de) 1976-07-16 1978-01-26 Schering Ag Verfahren zur herstellung von androstan-17-on-derivaten und deren verwendung
GB1581235A (en) 1977-04-04 1980-12-10 Glaxo Operations Ltd 11a-amino-3a-hydroxy-steroids
US4389345A (en) 1981-10-09 1983-06-21 G.D. Searle & Co. 3-Oxoestra-17-acetonitrile and unsaturated analogs
US4495102A (en) 1982-09-03 1985-01-22 G. D. Searle & Co. Aminoalkyl steroids
US5319115A (en) 1987-08-25 1994-06-07 Cocensys Inc. Method for making 3α-hydroxy, 3β-substituted-pregnanes
US5232917A (en) 1987-08-25 1993-08-03 University Of Southern California Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
US5120723A (en) 1987-08-25 1992-06-09 University Of Southern California Method, compositions, and compounds for modulating brain excitability
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
JPH06510999A (ja) 1991-09-13 1994-12-08 コセンシス・インコーポレイテッド ステロイド結合部位を有する新規ＧＡＢＡ↓ａレセプター
DE4232681C2 (de) 1992-09-29 1994-11-24 Sigma Tau Ind Farmaceuti 17-Phenyl- und 17-Furyl-14beta,5alpha-androstan- und androsten- Derivate, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Zusammensetzung
JP4008024B2 (ja) 1993-05-24 2007-11-14 パーデュー、ファーマ、リミテッド、パートナーシップ Ｇａｂａａレセプター複合体と相互作用させるための化合物
CZ300694A3 (en) 1993-12-02 1996-05-15 Akzo Nobel Nv Substituted 2beta-morpholinandrostane derivatives, process of their preparation, their use for preparing pharmaceutical preparations and pharmaceutical compositions containing thereof
EP0656365B1 (en) 1993-12-02 1997-04-09 Akzo Nobel N.V. Substituted 2beta-morpholinoandrostane derivatives
WO1995021617A1 (en) 1994-02-14 1995-08-17 Cocensys, Inc. Androstanes and pregnanes for allosteric modulation of gaba receptor
US5939545A (en) 1994-02-14 1999-08-17 Cocensys, Inc. Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series
AU3125695A (en) 1994-07-21 1996-02-22 Pharmacia & Upjohn Company Neurologically active aminosteroids
PT808325E (pt) 1994-11-23 2001-06-29 Cocensys Inc Series de androstanos e pregnanos para modulacao alosterica do receptor de gaba
HUP9901138A3 (en) 1995-06-06 1999-11-29 Cocensys Inc Irvine Neuroactive steroids of the androstane and pregnane series
WO1998005337A1 (en) 1996-08-01 1998-02-12 Cocensys, Inc. Use of gaba and nmda receptor ligands for the treatment of migraine headache
US5994334A (en) 1997-02-05 1999-11-30 University Of Maryland Androgen synthesis inhibitors
US5935545A (en) 1997-07-11 1999-08-10 E. I. Du Pont De Nemours And Company Process for producing an aqueous solution comprising ferric chloride
HUP0201818A3 (en) 1999-04-29 2004-04-28 Euro Celtique Sa 3alpha-hydroxy-3beta-methoxymethyl-21-heterocycle substituted steroids with anesthetic activity and pharmaceutical compositions containing the same
US7018406B2 (en) 1999-11-17 2006-03-28 Corevalve Sa Prosthetic valve for transluminal delivery
JP4070463B2 (ja) 2000-02-18 2008-04-02 大鵬薬品工業株式会社 ステロイド誘導体の製造法
US6855836B2 (en) 2000-10-26 2005-02-15 Jenapharm Gmbh & Co. Kg 17-Methylene steroids, process for their production and pharmaceutical compositions that contain these compounds
AU2002232509A1 (en) 2000-11-03 2002-05-15 Washington University Estrone-derivatives having cytoprotective activity
GR1003861B (el) 2000-12-29 2002-04-11 Νεα νευροστεροειδη που αλληλεπιδρουν με τον υποδοχεα gabaa.
AU2004224053B2 (en) 2003-03-24 2011-06-09 Sterix Limited Oestrogen derivatives as inhibitors of steroid sulphatase
US7781421B2 (en) 2003-05-29 2010-08-24 Washington University Neuroactive 13, 24-cyclo-18, 21-dinorcholanes and structurally related pentacyclic steriods
CN1882606A (zh) 2003-11-24 2006-12-20 默克公司 雌激素受体调节剂
US20090118248A1 (en) * 2004-04-23 2009-05-07 Euro-Celtique S.A. 3-Alpha-hydroxy 21-n-heteroaryl-pregnane derivatives for modulation of brain excitability and a process for the production thereof
WO2006037016A2 (en) 2004-09-27 2006-04-06 The Regents Of The University Of California Novel therapy for treatment of chronic degenerative brain diseases and nervous system injury
CA2582231A1 (en) 2004-09-29 2006-10-19 Hollis-Eden Pharmaceuticals, Inc. Steroid analogs and uses
AU2006256851C1 (en) 2005-06-09 2010-07-15 Euro-Celtique S.A. Pharmaceutical compositions of a neuroactive steroid and uses thereof
US20090203658A1 (en) 2007-01-08 2009-08-13 Duke University Neuroactive steroid compositions and methods of use therefor
DE102007027636A1 (de) 2007-06-12 2008-12-18 Bayer Schering Pharma Aktiengesellschaft 17ß-Cyano-18a-homo-19-nor-androst-4-en-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel
EP2155204B1 (en) 2007-06-15 2016-08-17 Research Triangle Institute Androstane and pregnane steroids with potent allosteric gaba receptor chloride ionophore modulating properties
GB0711948D0 (en) 2007-06-20 2007-08-01 Bionature E A Ltd Neurosteriod compounds
CN101412742B (zh) 2007-10-19 2013-07-31 天津金耀集团有限公司 一种抑制血管新生的硝酸酯药物
KR100958286B1 (ko) 2007-11-15 2010-05-19 한국과학기술원 ａ１Ｇ Ｔ―타입 칼슘 채널을 억제하여 본태성 진전증을예방 및 치료하는 방법
US20090264443A1 (en) 2008-04-18 2009-10-22 David Helton Treatment of organophosphate exposure with tetrahydroindolone arylpiperazine compounds
CN101585862B (zh) * 2008-05-20 2014-12-17 梅克芳股份公司 甾族化合物
CN101624414B (zh) 2008-07-07 2013-02-13 天津金耀集团有限公司 一种抑制血管新生的硝酸酯药物
CZ301216B6 (cs) 2008-07-10 2009-12-09 Ústav organické chemie a biochemie Akademie ved CR, v. v. i. Pregnanové anionické slouceniny, zpusob jejich výroby a jejich použití
US20100120733A1 (en) 2008-11-07 2010-05-13 Auspex Pharmaceuticals, Inc. Steroid modulators of glucocorticoid receptor
US20110152840A1 (en) 2009-12-23 2011-06-23 Drugtech Corporation Methods for reducing the occurrence of preterm delivery and other pregnancy-related conditions
EP2598513A1 (en) 2010-07-30 2013-06-05 Medexis S.A. Compounds and methods for treating neoplasia
AU2011343615A1 (en) 2010-12-15 2013-05-09 Harbor Biosciences, Inc. Methods and compounds for preparing 3alpha-oxygen substituted steroids
EP2675822A4 (en) 2011-02-15 2014-07-30 Socpra Sciences Et Génie S E C STEROID ALKALOIDS AND THEIR USE AS ANTIMICROBIAL AGENTS AGAINST MICROORGANISMS WITH ELECTRON TRANSPORT FAILURE AND AS MICROBIAL AGENT EXHAUSTERS AGAINST PATHOGENIC BACTERIA
CZ201181A3 (cs) 2011-02-15 2012-09-12 Ústav organické chemie a biochemie Akademie ved CR, v.v.i. Deriváty pregnanolonu substituované v poloze 3alfa kationickou skupinou, zpusob jejich výroby, jejich použití a prostredek je obsahující
US9388210B2 (en) 2011-02-25 2016-07-12 Washington University Neuroactive 17(20)-Z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same
ES2762098T3 (es) 2011-03-23 2020-05-22 Etsuro Ito Método y kit para medición de superalta sensibilidad de proteína y ácido nucleico, y nuevo sustrato enzimático
EP2736919A4 (en) 2011-07-29 2015-01-14 Univ California NEW 17-BETA-HETEROARYL-SUBSTITUTED STEROIDS AS MODULATORS OF GABAA RECEPTORS
AU2012304412A1 (en) 2011-09-08 2014-03-27 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
AU2012323888A1 (en) 2011-10-14 2014-05-29 Sage Therapeutics, Inc. 3,3 disubstituted 19-nor pregnane compounds, compositions, and uses thereof
WO2013188792A2 (en) 2012-06-15 2013-12-19 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
SG11201408501UA (en) 2012-06-19 2015-01-29 Intercept Pharmaceuticals Inc Preparation, uses and solid forms of obeticholic acid
US20140050789A1 (en) 2012-08-13 2014-02-20 The Regents Of The University Of California Mitigation of epileptic seizures by combination therapy using benzodiazepines and neurosteroids
US9765110B2 (en) 2012-10-08 2017-09-19 Washington University Neuroactive 19-alkoxy-17(20)-Z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same
WO2014071449A1 (en) 2012-11-09 2014-05-15 Goodchild Investments Pty Ltd Neuroactive steroids and their use to facilitate neuroprotection
SI3392260T1 (sl) 2012-12-18 2023-01-31 Washington University Nevroaktivni 19-alkoksi-17-substituirani steroidi, uporabni pri postopkih zdravljenja
US8939545B2 (en) 2012-12-20 2015-01-27 Eastman Kodak Company Inkjet printing with managed airflow for condensation control
CA2831054C (en) 2013-01-09 2016-08-30 Sapna Life Sciences Corp. Formulations, and methods for their use in treatment of neuropathology and neurodegeneration as a result of traumatic injury
WO2014108808A2 (en) 2013-01-09 2014-07-17 Henry James Lorne Pharmaceutical formulations for the treatment and prevention of trauma-induced neuropathology and neurodegeneration
GB201302368D0 (en) 2013-02-11 2013-03-27 Univ Bath Compound
US9512170B2 (en) 2013-03-01 2016-12-06 Washington University Neuroactive 13, 17-substituted steroids as modulators for GABA type-A receptors
US9562026B2 (en) 2013-03-14 2017-02-07 Washington University Neuroactive substituted cyclopent[a]anthracenes as modulators for GABA type-A receptors
WO2014169836A1 (en) 2013-04-17 2014-10-23 Sage Therapeutics, Inc. 19-nor neuroactive steroids and methods of use thereof
US9725481B2 (en) 2013-04-17 2017-08-08 Sage Therapeutics, Inc. 19-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof
CN117304245A (zh) 2013-04-17 2023-12-29 萨奇治疗股份有限公司 刺激神经活性的19-去甲类固醇及其使用方法
BR112015026380A8 (pt) 2013-04-17 2019-12-31 Sage Therapeutics Inc esteróides de c21-n-pirazolil 19-nor c3,3-dissubstituídos e métodos de uso destes
AU2014290400B2 (en) 2013-07-19 2019-12-05 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
EP3488852B1 (en) 2013-08-23 2020-10-28 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
KR20240066304A (ko) 2014-05-29 2024-05-14 세이지 테라퓨틱스, 인크. 신경활성 스테로이드, 조성물, 및 그의 용도
US10246482B2 (en) 2014-06-18 2019-04-02 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
US10172870B2 (en) 2014-09-02 2019-01-08 The Texas A&M University System Method of treating organophosphate intoxication by administration of neurosteroids
AU2015331597B2 (en) 2014-10-16 2020-04-30 Sage Therapeutics, Inc. Compositions and methods for treating CNS disorders
CN117024502A (zh) 2014-10-16 2023-11-10 萨奇治疗股份有限公司 靶向cns障碍的组合物和方法
EP3719029A1 (en) 2014-11-27 2020-10-07 Sage Therapeutics, Inc. Compositions for inducing sedation
DK3250210T3 (da) 2015-01-26 2021-03-08 Sage Therapeutics Inc Sammensætninger og fremgangsmåder til behandling af cns-forstyrrelser
CN105985396A (zh) 2015-02-16 2016-10-05 苏州泽璟生物制药有限公司 氘代鹅去氧胆酸衍生物以及包含该化合物的药物组合物
WO2016134301A2 (en) 2015-02-20 2016-08-25 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
UY36741A (es) 2015-06-21 2016-12-30 Prevacus Inc Compuesto de esteroide c-20, sus composiciones y usos para tratar la lesión cerebral traumática (tbi), que incluye las conmociones cerebrales
CN108350021A (zh) 2015-09-08 2018-07-31 视点医疗公司 用于治疗眼科疾病的化合物和制剂
WO2017049044A1 (en) 2015-09-16 2017-03-23 Bartolucci Giampiero Ursodeoxycholic acid and brain disorders
MX2018004376A (es) 2015-10-16 2018-08-01 Marinus Pharmaceuticals Inc Formulaciones inyectables de neuroesteroides que contienen nanoparticulas.
WO2017087864A1 (en) 2015-11-20 2017-05-26 Sage Therapeutics, Inc. Compounds and methods of their use
KR20220084418A (ko) 2016-03-08 2022-06-21 세이지 테라퓨틱스, 인크. 신경활성 스테로이드, 조성물, 및 그의 용도
US10226550B2 (en) 2016-03-11 2019-03-12 Brigham Young University Cationic steroidal antimicrobial compositions for the treatment of dermal tissue
NZ749664A (en) 2016-07-11 2025-08-29 Sage Therapeutics Inc C17, c20, and c21 substituted neuroactive steroids and their methods of use
JP7065825B2 (ja) 2016-07-11 2022-05-12 セージ セラピューティクス， インコーポレイテッド Ｃ７、ｃ１２、およびｃ１６置換神経刺激性ステロイドおよびそれらの使用方法
AR109393A1 (es) 2016-08-23 2018-11-28 Sage Therapeutics Inc Un esteroide 19-nor-c21-pirazolilo c3,3-disustituido cristalino
US10391105B2 (en) 2016-09-09 2019-08-27 Marinus Pharmaceuticals Inc. Methods of treating certain depressive disorders and delirium tremens
CN108727453A (zh) 2017-04-20 2018-11-02 华东理工大学 新型pd-1抑制剂及其应用
US11266663B2 (en) 2017-06-23 2022-03-08 The Board Of Trustees Of The University Of Illinois Treatment of neuropsychiatric disorders with neurosteroids and analogues thereof
WO2019018119A1 (en) 2017-07-18 2019-01-24 Pairnomix, Llc METHODS FOR TREATING EPILEPSY AND DISORDERS ASSOCIATED WITH KCNTI
CA3073925A1 (en) 2017-08-31 2019-03-07 Takeda Pharmaceutical Company Limited Treatment of cns conditions
WO2019051264A1 (en) * 2017-09-07 2019-03-14 Sage Therapeutics, Inc. NEUROACTIVE STEROIDS AND METHODS OF USE
JP7312169B2 (ja) 2017-11-10 2023-07-20 マリナス ファーマシューティカルズ インコーポレイテッド 遺伝性てんかん性障害の処置に使用するガナキソロン
JP7382326B2 (ja) 2017-12-22 2023-11-16 セージ セラピューティクス， インコーポレイテッド Ｃｎｓ障害の処置のための組成物および方法
MA51316A (fr) 2017-12-22 2020-10-28 Sage Therapeutics Inc Compositions et méthodes permettant de traiter les troubles du snc
MX2020008422A (es) 2018-02-11 2020-09-21 Jiangsu Hansoh Pharmaceutical Group Co Ltd Regulador derivado de esteroides, metodo para prepararlos y usos de los mismos.
TW202014192A (zh) 2018-05-04 2020-04-16 加拿大商阿爾宙斯製藥有限公司 神經類固醇衍生物及其用途
EP3902818A1 (en) 2018-12-05 2021-11-03 Sage Therapeutics, Inc. Neuroactive steroids and their methods of use
WO2020210116A1 (en) 2019-04-08 2020-10-15 Athenen Therapeutics, Inc. Steroids with altered pharmacokinetic properties and methods of use thereof
WO2020210117A1 (en) * 2019-04-08 2020-10-15 Athenen Therapeutics, Inc. Steroids with altered pharmacokinetic properties and methods of use thereof
TWI896548B (zh) 2019-06-27 2025-09-11 美商賽吉醫療公司 用於治療cns病症之組合物及方法
WO2020264509A1 (en) 2019-06-27 2020-12-30 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
US20230118577A1 (en) * 2020-01-12 2023-04-20 Brii Biosciences, Inc. Neuroactive steroids and pharmaceutical composition containing the same

Also Published As

Publication number Publication date
DOP2023000152A (es) 2024-01-15
JP7670626B2 (ja) 2025-04-30
TW202535415A (zh) 2025-09-16
US20200377547A1 (en) 2020-12-03
CA3139554A1 (en) 2020-12-03
JOP20210293A1 (ar) 2023-01-30
MA56046A (fr) 2022-04-06
AU2025234152A1 (en) 2025-10-02
CR20210629A (es) 2022-03-22
MX2024009539A (es) 2024-08-19
BR112021024033A2 (pt) 2022-02-08
CN114206900A (zh) 2022-03-18
TWI864010B (zh) 2024-12-01
US20250250296A1 (en) 2025-08-07
MX2021014515A (es) 2022-03-22
PE20230244A1 (es) 2023-02-07
PH12021553005A1 (en) 2023-08-14
JP2025039721A (ja) 2025-03-21
KR20220016098A (ko) 2022-02-08
IL288410A (en) 2022-01-01
EP3976628A1 (en) 2022-04-06
WO2020243488A1 (en) 2020-12-03
SA521430928B1 (ar) 2025-06-12
JP2022534424A (ja) 2022-07-29
DOP2021000237A (es) 2022-06-15
ECSP21091076A (es) 2022-01-31
US20240279268A1 (en) 2024-08-22
US20250236639A1 (en) 2025-07-24
US20230250128A1 (en) 2023-08-10
CL2021003166A1 (es) 2022-09-30
IL288410B1 (en) 2026-01-01
MX2024009540A (es) 2024-08-19
US11643434B2 (en) 2023-05-09
SG11202112391UA (en) 2021-12-30
TW202110457A (zh) 2021-03-16
AU2020284110A1 (en) 2021-11-25
CO2021015890A2 (es) 2021-11-30
CR20240234A (es) 2024-07-09

Similar Documents

Publication Publication Date Title
AR119047A1 (es) Esteroides neuroactivos como moduladores de gabaa y su uso en el tratamiento de trastornos del snc
AR119305A1 (es) Composiciones y métodos para el tratamiento de los trastornos del snc
AR117264A1 (es) Esteroides neuroactivos y métodos para su uso
AR116695A1 (es) Los neuroesteroides y sus métodos de uso
AR115822A1 (es) Compuestos de sulfonimidamida como inhibidores de la actividad de interleuquina-1
AR094876A1 (es) Derivados de ácido betulínico modificados con alquilo c-3 y alquenilo
AR111295A1 (es) Composiciones de pirrolopirrol como activadores de piruvato quinasa (pkr)
AR111407A1 (es) Compuestos inhibidores de ask1 y usos de los mismos
AR114044A1 (es) Composiciones y métodos para el tratamiento de trastornos en el sistema nervioso central
AR115085A1 (es) DERIVADOS DE 3-AMINO-2,4,6-TRIAZINA COMO INHIBIDORES DE LA TIROSINA CINASA DE BRUTON (Btk)
PE20201414A1 (es) Derivado policiclico de piridona
EP4257137A3 (en) Polycyclic carbamoylpyridone derivatives for the treatment of hiv
AR098721A1 (es) Inhibidores de biarilo de tirosina quinasa de bruton
EP3752144A4 (en) TETRACYCLIC HETEROCYCLENE COMPOUNDS USEFUL AS HIV INTEGRASE INHIBITORS
AR116771A1 (es) Los neuroesteroides activos y sus métodos de uso
EP3784241A4 (en) TETRACYCLIC HETEROCYCLENIC COMPOUNDS USEFUL AS HIV INTEGRASE INHIBITORS
AR123648A1 (es) Compuestos de carbamoilpiridona tricíclicos puenteados y sus usos
EP3801543A4 (en) TETRACYCLIC HETEROCYCLENIC COMPOUNDS USEFUL AS HIV INTEGRASE INHIBITORS
AR099890A1 (es) Inhibidores de histona demetilasas
AR125213A2 (es) Concentrado emulsionable que comprende un herbicida de ácido picolínico
PE20081113A1 (es) Inhibidores virales policiclicos
AR119309A1 (es) Composiciones y métodos para el tratamiento de los trastornos del snc
CO2018007788A2 (es) Compuesto novedoso de ácido bisfosfónico
AR129523A1 (es) Inhibidores de cgas
AR117493A1 (es) Esteroides neuroactivos y composiciones con los mismos